SaveMe PDF Print E-mail

A Modular Nanosystems Platform for Advanced Cancer Management: Nano-vehicles; Tumor Targeting and Penetration Agents; Molecular Imaging, Degradome based Therapy

 

Project Budget: 14,046,854 Euro

SaveMe project will address current urgent needs for pancreatic cancer diagnosis and treatment by exploiting partners’ expertise and most recent research achievements for the design and development of novel modular nanosystems platform integrating new functionalized nano-core particles and active agents. The modular platform will enable the design of diverse active nanosystems per diagnostic or therapeutic application as defined by their active agent compositions. For diagnostics, superior tracers will be developed for molecular MR/PET and gamma camera imaging, enabling efficient diagnosis and guided surgery respectively. Novel functionalized nano-core systems will be conjugated with semi-confluent active shell layer. Three types of shell layers will be design: (1) novel iron oxide nanoparticles as advanced MRI contrast agents and/or (2) DOTA complexes for MRI (with Gd3+), or PET (with Ga-68), or gamma camera (with Ga-69); (3) Integrating within one tracer both iron oxide nanoparticles and DOTA-Ga-68 complexes for a sequential or simultaneous MR/PET imaging. For therapeutics, active nanosystems will be developed to deliver (1) therapeutic siRNAs or (2) anti-MP-inhibitory-scFVs. These non-classic anti-tumor drugs will be designed based on an extensive tumor degradome analysis for combining blockage of selective matrix MPs, thus preventing basic invasive and metastasis steps, with siRNA based neutralization of secondary molecular effects induced by the specific protease inhibition. Individualized degradome analysis will be developed for potential profiling of anti-MP and siRNAs based therapy per patient. To facilitate the above diagnostics and therapeutic effects, advanced tumor targeting and penetration active agents will be linked to nano-core functionalized groups, including a biocompatible PEG layer linked to tumor selective MMP substrate molecules and highly safe and potent novel somatostatin analogue peptides targeting SSTR overexpression.

The consortium

Beneficiary name

Country

Tel Aviv University - Coordinator

IL

Wilhelminenspital

AT

UniversitätsKlinikum Heidelberg

DE

Bar Ilan University

IL

University of Bologna – INSTM

IT

Johann Wolfgang Goethe-Universität

DE

Nanosystem LTD

RU

CIDETEC

ES

CIC biomaGUNE

ES

COLOROBBIA ITALIA S.p.A.

IT

Sheba Medical Center

IL

University of East Anglia

UK

Technischen Universität München - Klinikum rechts der Isar

DE

Katholiek University of Leuven

BE

Weizmann Institute of Science

IL

Institute of Bioorganic Chemistry, Russian Academy of Sciences

RU

nhance Technologies Limited

UK

Filarete Servizi  S.r.l

IT

GE Healthcare

IL

OSM-DAN Ltd.

SW

Link to SaveMe website www.fp7-saveme.com